A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Epistemonikos ID: 6d794d2bc0fce8c60226e9db697b7949cce54c13
First added on: May 21, 2024